HRS-4642
Drug timelines are a Plus or Pro feature.
14 regulatory and trial events tracked for HRS-4642, covering 2024-08-09 to 2026-04-15. Get the full timeline:
Most recent: Clinical Trial Update: A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer [Phase 2]